The activity of an analogue of MPF (β-endorphin 28–31) in a rat model of Parkinson's disease

A single intrastriatal injection of a slow release formulation of a metabolically-stable MPF analogue was given to rats with lesioned right nigrostriatal pathways. After 6 weeks the turning behaviour of the rats in response to d-amphetamine began to decline, and after 12 weeks the reduction was mark...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Brain research 1993-04, Vol.610 (1), p.166-168
Hauptverfasser:	Ensor, D.M., Morley, J.S., Redfern, R.M., Miles, J.B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Animals beta-Endorphin - administration & dosage beta-Endorphin - analogs & derivatives Biological and medical sciences Brain transplant Delayed-Action Preparations Disease Models, Animal Dopamine Male Medical sciences Molecular Sequence Data MPF Nervous system involvement in other diseases. Miscellaneous Neurology Parkinson Disease - drug therapy Parkinson's disease Peptide Fragments - administration & dosage Rats Rats, Wistar β-Endorphin(28–31)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A single intrastriatal injection of a slow release formulation of a metabolically-stable MPF analogue was given to rats with lesioned right nigrostriatal pathways. After 6 weeks the turning behaviour of the rats in response to d-amphetamine began to decline, and after 12 weeks the reduction was marked and consistent. The implication of our results in the use of intracerebral grafts in parkinsonian patients is discussed.
ISSN:	0006-8993 1872-6240
DOI:	10.1016/0006-8993(93)91232-H